Fortress Biotech (FBIO) Receives Daily Media Sentiment Rating of 0.10

Media coverage about Fortress Biotech (NASDAQ:FBIO) has trended somewhat positive this week, Accern reports. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Fortress Biotech earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 44.8229708126967 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news stories that may have impacted Accern’s scoring:

How to Become a New Pot Stock Millionaire

Shares of FBIO stock traded down $0.23 on Friday, hitting $4.92. The stock had a trading volume of 159,568 shares, compared to its average volume of 235,413. The firm has a market cap of $264.41, a P/E ratio of -3.06 and a beta of 0.45. The company has a quick ratio of 2.69, a current ratio of 2.72 and a debt-to-equity ratio of 0.44. Fortress Biotech has a fifty-two week low of $3.13 and a fifty-two week high of $5.54.

Several research analysts have recently commented on FBIO shares. HC Wainwright set a $11.00 target price on Fortress Biotech and gave the stock a “buy” rating in a report on Tuesday, January 2nd. B. Riley started coverage on Fortress Biotech in a report on Wednesday, February 28th. They issued a “buy” rating and a $10.00 target price on the stock. BidaskClub raised Fortress Biotech from a “sell” rating to a “hold” rating in a report on Sunday, March 11th. ValuEngine raised Fortress Biotech from a “sell” rating to a “hold” rating in a report on Thursday, March 1st. Finally, Zacks Investment Research raised Fortress Biotech from a “sell” rating to a “hold” rating in a report on Tuesday, February 6th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $10.75.

TRADEMARK VIOLATION NOTICE: “Fortress Biotech (FBIO) Receives Daily Media Sentiment Rating of 0.10” was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3296191/fortress-biotech-fbio-receives-daily-media-sentiment-rating-of-0-10.html.

About Fortress Biotech

Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.

Insider Buying and Selling by Quarter for Fortress Biotech (NASDAQ:FBIO)

Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

TAKKT  Given a €24.30 Price Target at Warburg Research
TAKKT Given a €24.30 Price Target at Warburg Research
BuzzCoin  Trading 31.7% Higher  This Week
BuzzCoin Trading 31.7% Higher This Week
LSC Communications  Expected to Post Earnings of $0.17 Per Share
LSC Communications Expected to Post Earnings of $0.17 Per Share
Somewhat Positive Press Coverage Somewhat Unlikely to Affect AGCO  Share Price
Somewhat Positive Press Coverage Somewhat Unlikely to Affect AGCO Share Price
AquariusCoin  Tops 1-Day Volume of $6,459.00
AquariusCoin Tops 1-Day Volume of $6,459.00
Super Bitcoin  Trading 15.4% Higher  This Week
Super Bitcoin Trading 15.4% Higher This Week


© 2006-2018 Ticker Report. Google+.